Leading the Way in Life Science Technologies

GEN Exclusives

More »

Tutorials

More »
Jun 1, 2010 (Vol. 30, No. 11)

Autoantibodies as Diagnostic Biomarkers

Readily Detectable Agents Are Suitable for Presymptomatic and Early Diagnosis of Disease

  • Conclusion

    Biomarkers must be both easy to detect and measure if they are to be used clinically. In addition, the use of a panel of biomarkers as opposed to a single biomarker can offer more robust and accurate results while minimizing the risk of false positives.

    As such, circulating autoantibodies represent a pertinent source of early diagnostic and presymptomatic biomarkers for a number of pathologies including certain cancers and autoimmune diseases.

    OGT has experience in the development of such panels using a number of different technologies. Core to the autoantibody area is Sense Proteomic’s functional protein array technology. This uses a BCCP fusion tag to provide the assurance that immobilized proteins are properly folded and hence native conformational epitopes are presented on the surface of each protein. As a result, the diagnostic autoantibody biomarker panels developed form  sensitive and highly selective pathology fingerprints.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »